Nudoic 180mg Tablet contains bempedoic acid, an oral lipid-lowering agent indicated for the treatment of hypercholesterolemia and mixed dyslipidemia. Bempedoic acid acts as an adenosine triphosphate-citrate lyase (ACL) inhibitor, targeting a key enzyme involved in the cholesterol biosynthesis pathway upstream of HMG-CoA reductase. By inhibiting ACL, Nudoic effectively reduces low-density lipoprotein cholesterol (LDL-C) levels, thereby contributing to cardiovascular risk reduction in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Nudoic is typically prescribed as an adjunct to diet and maximally tolerated statin therapy in patients who require additional LDL-C lowering. The once-daily oral administration of Nudoic 180mg allows for convenient dosing. Clinical studies have demonstrated that bempedoic acid significantly lowers LDL-C levels with a favorable safety profile, exhibiting minimal muscle-related adverse effects compared to statins. Common side effects may include increased uric acid levels and mild gastrointestinal symptoms. Nudoic is contraindicated in patients with known hypersensitivity to bempedoic acid and should be used with caution in those with a history of tendon disorders or gout. Regular monitoring of lipid profiles and liver function tests is recommended during therapy to ensure efficacy and safety.